HLscience Co., Ltd.
Financials
Valuation Metrics
HLscience Co., Ltd.'s Market Cap is ₩322B. At end of 2025 it was ₩436B. Ranked #2002 of 2,410 in KR market (top 83%), #1264 of 1,631 on KOSDAQ (top 77%), #41 of 56 in Household & Personal Products (top 73%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 32.19B KRW | KR#2,002/2,410 Sec#41/56 |
| Revenue | 10.44B KRW | KR#2,279/2,410 Sec#52/56 |
| Net Income | -11.22B KRW | KR—/2,410 Sec—/56 |
| Total Assets | 85.04B KRW | KR#1,901/2,410 Sec#41/56 |
| Net Assets | 82.77B KRW | KR#1,560/2,410 Sec#32/56 |
| Employees | 84 | KR#1,775/2,410 Sec#42/56 |
| Value | ||
| P/B | 0.39x | KR#610/2,410 Sec#9/56 |
| P/S | 3.08x | KR#2,013/2,410 Sec#51/56 |
| FCF Yield | -23.34% | KR—/2,410 Sec—/56 |
| Profitability | ||
| ROE | -13.55% | KR#1,994/2,410 Sec#46/56 |
| ROA | -13.19% | KR#2,154/2,410 Sec#51/56 |
| Op. Margin | -96.28% | KR#2,286/2,410 Sec#55/56 |
| Revenue Growth | -42.45% | KR#2,262/2,410 Sec#54/56 |
| Financial Health | ||
| Debt Ratio | 2.75% | KR#12/2,410 Sec#2/56 |
| Total Debt | 0 KRW | KR—/2,410 Sec—/56 |
| FCF | -7.51B KRW | KR#1,610/2,410 Sec#45/56 |
| Cash | 1.78B KRW | KR#2,260/2,410 Sec#53/56 |
| Current Ratio | 14.74x | KR#51/2,410 Sec#2/56 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,410 Sec—/56 |
| Performance | ||
| 1Y Return | -33.37% | KR#1,578/2,410 Sec#34/56 |
| 1M Return | 14.59% | KR#104/2,410 Sec#1/56 |
| From 52W High | -41.12% | KR#823/2,410 Sec#23/56 |
| 1Y MDD | -46.48% | KR#850/2,410 Sec#29/56 |
| Trading | ||
| Volume | 3,368 shares | KR#2,303/2,410 Sec#56/56 |
| Trading Value | 20.0M KRW | KR#2,283/2,410 Sec#52/56 |
| Foreign Own. | 0.83% | KR#2,083/2,410 Sec#43/56 |
| Per Share | ||
| EPS | -2,080 KRW | KR—/2,410 Sec—/56 |
| BPS | 15,350 KRW | KR#687/2,410 Sec#14/56 |
Company Info
HL Science, originally Geongang Sarang, was founded in 2000 and listed on KOSDAQ in 2016. In 2022, it completed Korea's first Ministry of Food and Drug Safety-approved individually recognized raw material CDMO smart factory in Chungju, Chungcheongbuk-do. The company operates as a technology platform enterprise, focusing on research into new biomaterials and new technologies for bio healthcare, encompassing R&D, manufacturing, and sales. It has developed 12 individually recognized raw materials, securing 48 domestic and international patent registrations and 16 patent applications, establishing an integrated Value Chain system. Headquartered in Uiwang, Gyeonggi-do.